Dr. Bin Xie discusses the current immuno-oncology drug development landscape and different humanized models available for drug testing, including LIDE's unique human PBMC/cancer cell co-transfer model. He also evaluates real-world case studies and describes the investigation of potential mechanisms by imaging mass cytometry.
LIDE's innovative MiniPDX, a rapid 7-day in vivo drug efficacy test for oncology therapeutics. Achieve high correlations with traditional PDX and clinical endpoints, making it an effective, time-efficient, and cost-effective option for testing targeted drugs and more. Boost your drug development today with MiniPDX.